The function of Synoviolin on liver fibrosis in Non-alcoholic steatohepatitis

• Project/Area Number: 15K09024
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Tokyo Medical University
• Principal Investigator: NAKAMURA IKUO 東京医科大学, 医学部, 准教授 (40251243)
• Co-Investigator(Kenkyū-buntansha): 中島 利博 東京医科大学, 医学部, 教授 (90260752)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 非アルコール性脂肪性肝炎 / 肝線維化 / Synoviolin

Outline of Final Research Achievements

The aim of the study was to examine the function of synoviolin, that was one of the ER protein found in synovia of rheumatoid arthritis, on liver fibrosis in non-alcoholic steatohepatittis (NASH). The mouse NAFLD/NASH model induced by streptozotocin and high-fat diet was used in this study. LS-102 was one of the specific inhibitor of synoviolin, The degree of liver fibrosis in 12 week after birth in this mouse model was pathologically estimated and compared between LS-102 administration group and control group. It seemed that the degree of liver fibrosis in LS-102 administration group was lower compared with that of control group. Therefore, the results in this study suggested that inhibition of synoviolin function could reduce the fibrosis of liver in this mouse NAFLD/NASH model.